The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes by Thomas, M. C. et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2012, Article ID 456529, 10 pages
doi:10.1155/2012/456529
Review Article
The Renoprotective Actions of Peroxisome Proliferator-Activated
ReceptorsAgonists in Diabetes
M. C.Thomas, K.A. Jandeleit-Dahm,andC.Tikellis
Division of Diabetic Complications, Baker IDI Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC 8008, Australia
Correspondence should be addressed to C. Tikellis, chris.tikellis@bakeridi.edu.au
Received 9 September 2011; Revised 21 November 2011; Accepted 21 November 2011
Academic Editor: Brian Finck
Copyright © 2012 M. C. Thomas et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pharmaceutical agonists of peroxisome proliferator-activated receptors (PPARs) are widely used in the management of type 2
diabetes, chieﬂy as lipid-lowering agents and oral hypoglycaemic agents. Although most of the focus has been placed on their
cardiovascular eﬀects, both positive and negative, these agents also have signiﬁcant renoprotective actions in the diabetic kidney.
Over and above action on metabolic control and eﬀects on blood pressure, PPAR agonists also appear to have independent eﬀects
on a number of critical pathways that are implicated in the development and progression of diabetic kidney disease, including
oxidative stress, inﬂammation, hypertrophy, and podocyte function. This review will examine these direct and indirect actions of
PPAR agonists in the diabetic kidney and explore recent ﬁndings of clinical trials of PPAR agonists in patients with diabetes.
1.Introduction
Pharmaceutical agonists of peroxisome proliferator-activat-
ed receptors (PPARs) are widely used in the management of
type2diabetes.PPARαagonists,knownasﬁbrates,havebeen
used for over 40 years in patients with diabetes, chieﬂy as
lipid-lowering agents. Over the last decade, PPARγ agonists,
known as thiazolidinediones (TZDs) or glitazones, have also
come into clinical use as oral hypoglycaemic agents. Selective
agonists of a third isoform of PPAR, PPAR β/δ are also
under clinical development for treatment of the metabolic
syndrome [1]. Although most focus has been placed on
their metabolic and cardiovascular eﬀects, these agents also
have direct and indirect actions in the diabetic kidney.
Such actions are potentially important as the presence and
severity of kidney disease adversely aﬀects the well being
of individuals with diabetes and signiﬁcantly contributes to
disease morbidity and increases their risk of a premature
death. For example, we have shown that in Finnish adults
withtype 1diabetes excessmortality associated withdiabetes
is almost entirely conﬁned to those with chronic kidney
disease (CKD) [2]. Equally, in patients with type 2 diabetes,
kidney disease is associated with an increase in the risk
of death [3, 4]. Consequently, long-term beneﬁts from
preventing and managing diabetic kidney disease may prove
tobeamongthemostimportantactionsoftheseagents.This
review will examine the indirect and direct actions of PPAR
agonists speciﬁcally in the diabetic kidney and explore recent
ﬁndings of clinical trials of PPAR agonists in patients with
diabetes.
2. The Expressionof PPARs in the Kidney
PPARs are ligand-activated nuclear transcription factors that
have complex biologic eﬀects, resulting from the transacti-
vation or transrepression of dozens of genes [5]. Transac-
tivation eﬀects require dimerisation of PPAR with retinoid
X receptor (RXR), followed by translocation to the nucleus
where upon the PPAR: RXR dimer binds to the PPAR re-
sponse element of target genes and induces the expression
of these genes [5]. Ligand-dependent transrepression is
mediated via interference with nuclear receptors such as
activator protein-1 (AP-1) and nuclear factor-κB( N F - κB)
[6]. The relative importance of activation versus repression
pathways for the renal action of PAAR agonists remains to be
established.Moreover,thereisevidencethatnotallPPARlig-
ands stimulate transactivation and transrepression pathways
to a similar extent [7], and their relative importance may be
diﬀerent in diﬀerent tissues.2 PPAR Research
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Figure 1:TreatmentwithPPARagonists,gemﬁbrozilandrosiglitazonereducesglomerulosclerosis(a)andtubulointerstitialexpansion(b)in
streptozotocin diabetic apolipoprotein E knockout mice [25]. Data shows mean ± SEM; ∗versus control P<0.05, #versus diabetes P<0.05).
In the kidney, PPARα is expressed in proximal tubules
and medullary thick ascending limbs where it is thought to
be involved in the regulation of protein-degradation systems
through maintenance of ATP homeostasis [8], control of
fatty acid β-oxidation [9], and regulation of cytochrome
P450 in proximal tubules [10]. PPARγ is predominantly
expressed in medullary collecting ducts and pelvic urothe-
lium [11–13], the latter site is potentially important for the
putative link between PPARγ agonists and transitional cell
cancer [14]. Studies using more speciﬁc antibodies suggest
that lower level PPARγ expression is observed in glomeruli,
proximal and distal tubules, the loop of Henle, medullary
collecting ducts, and intima-media of renal vasculature [15].
The third isoform of PPAR, PPAR β/δ is also ubiquitously
expressed in the kidney, with the highest levels observed in
theproximalstraighttubuleinrenalcortexandmedulla[16].
The expression and activity of PPARs is signiﬁcantly
modiﬁed by diabetes, partly reﬂecting the abnormal meta-
bolic milieu and partly contributing to it. For example, the
expression of PPARα is markedly reduced in pancreatic islets
of obese prediabetic Zucker diabetic fatty rats [17] and in
isolated rat pancreatic islets in response to elevated glucose
levels [18]. However, the expression of PPARs in the diabetic
kidney appears to be generally increased. For example,
the expression of PPARα is upregulated in glomeruli and
cortical tubules of diabetic db/db mice [19] and in renal
cells following exposure to high glucose levels [20]. Similar
ﬁndings have also been reported with the induction of
PPARγ [21, 22]a n dP P A Rβ/δ [23] expression in the diabetic
kidney. Increased expression of PPARα and PPARγ has also
been described in renal biopsies from patients with CKD,
correlating inversely with extent of proteinuria and kidney
function [24].
3. The Renoprotective Actions of
PPARα Agonists
3.1. Experimental Studies. There is strong evidence that
PPARα agonists both have independent renoprotective ac-
tions in experimental diabetes. For example, we have
shown that treatment with the PPARα agonist, gemﬁbrozil
(100mg/kg/day), is able to attenuate albuminuria, glomeru-
losclerosis, tubulointerstitial expansion, and collagen IV
deposition associated with streptozotocin-induced diabetes
(Figure 1)[ 25]. Importantly, this is a model of type 1 dia-
betes, meaning that these renoprotective eﬀects are observed
in the absence of changes in glucose, insulin, or lipid levels or
areductioninbloodpressure,suggestingadirectmechanism
of action (see below). Similar renoprotective actions on
diabetic kidney disease have also been observed in other
rodent models, including db/db mice, obese Zucker rats
and OLETF (Otsuka Long-Evans Tokushima Fatty) rats,
although indirect actions through amelioration of dyslipi-
demia may have contributed to some of these ﬁndings [26–
31]. By contrast, in diabetic PPARα-knockout mice, diabetic
nephropathy is more severe than in wild-type mice [20].
3.2. Clinical Studies with PPARα. In clinical studies, signif-
icant reductions in albuminuria have also been reported
following the use of ﬁbrates in patients with diabetes. For
example, in the diabetes atherosclerosis interventional study
(DAIS)fenoﬁbratereducedalbuminuriaandtheriskforpro-
gression, independent of changes in lipid parameters [34].
Albuminuria was also reduced in the FIELD (fenoﬁbrate
interventionandeventloweringindiabetes)studyinpatients
with type 2 diabetes, with reduced risk of progression in
patients receiving fenoﬁbrate (9.5% versus 11.0%, P<0.05)
[35]. Furthermore, regression of albuminuria was also in-
creased in patients receiving fenoﬁbrate (9.4% versus 8.2%,
P<0.05). Microalbuminuria was also modestly reduced in
the ACCORD-LIPID trial [36] .T h e s er e n o p r o t e c t i v ee ﬀects
appeared to be independent of the degree of lipid-lowering
or starting lipid concentrations, leading to the suggestion
that direct eﬀects arising from PPARα receptor activation
may be mediating its beneﬁts. There are very few large
studies with other ﬁbrates that included renal function as
a secondary outcome, although a few small studies have
reported reduction in microalbuminuria with gemﬁbrozil
[37].PPAR Research 3
3.3. Mechanisms of Action. Diabetic dyslipidaemia is a ma-
jor reversible risk factor for diabetic CKD [38–41]. A
range of quantitative and qualitative lipid and lipoprotein
abnormalities are observed in patients with diabetes and
nephropathy,includingincreasedplasmatriglycerides,small,
dense LDL, and reduced HDL cholesterol levels [42]. In-
creased triglyceride levels are largely due to the accumula-
tion of very low density lipoprotein (VLDL), chylomicron
remnants, and intermediate density lipoprotein (IDL) par-
ticles in the plasma. This is thought to reﬂect both the
overproduction of triglyceride-rich VLDL (due to increased
ﬂux of free fatty acids and hepatic resistance to the eﬀects
insulin), together with reduced catabolism (associated with
reduced of lipoprotein lipase activity) [43]. Although LDL
cholesterol levels in patients with type 2 diabetes are often
within the normal range, there remain signiﬁcant distur-
bances in LDL metabolism in diabetes, especially in patients
with nephropathy. For example, LDL production is generally
reduced, while impaired turnover of LDL particles [44]p r o -
motes glycoxidative modiﬁcation of lipoprotein particles.
These high levels of oxidized LDL increase the production
of cytokines associated with inﬂammation and chemotaxis
[41]. Diabetes is also associated with the accumulation of
small dense, triglyceride-rich, LDL particles. HDL choles-
terol levels are invariably reduced in patients with type 2
diabetes, reﬂecting increased catabolism of HDL particles. In
addition, HDL particles become enriched with triglycerides,
in an attempt to cope with an increased VLDL burden.
Activation of PPARα with the use of ﬁbrates in patients
with diabetes increases HDL cholesterol [45, 46], decreases
triglyceride levels, and shifts LDL-C distribution toward
larger particles [47]. On their own, these improvements in
the lipid proﬁle would be anticipated to lead indirectly to
a reduction in renal dysfunction associated with diabetes.
For example, in a high fat feeding model, which speciﬁcally
results in renal lipotoxicity, PPARα agonists such as fenoﬁ-
brate can inhibit the development of renal injury [48].
Over and above their eﬀects on lipid metabolism, PPARα
agonists also appear to have direct eﬀects on a number of
critical pathways that are implicated in the development and
progression of diabetic kidney disease. None of these actions
occurs in isolation but appear synergistically intertwined,
consistent with the key role of the PPAR signalling pathway
as a metabolic and cellular regulator. Such actions may not
even be mediated through PPAR receptors. For example,
there are some data to suggest that PPARα agonists also have
activities through PPAR-independent pathways. It is known,
for example, that some of the actions of ﬁbrates persist in
PPARα-deﬁcient mice [49]. PPARα agonists are also able
to directly antagonize the activities of other transcription
factors including AP-1, signal transducers and activators of
transcription1(STAT-1),andNFκB,possiblybytransrepres-
sion of other nuclear receptors [50, 51].
3.3.1.PPARαAgonistsasRenalAntioxidants. Renaldiseasein
diabetic patients is characterized by oxidative modiﬁcation
of proteins, lipids, carbohydrates and DNA associated with
increased production of oxidants or reactive oxygen species
apoE
0
100
50
150
#
200
apoE/diab apoE/diab +
Gem
apoE/diab +
Rosi
∗
∗#
R
L
U
/
1
0
 
m
g
 
t
i
s
s
u
e
Figure 2: Increased superoxide production in the diabetic vascu-
lature is signiﬁcantly reduced following treatment with PPAR ago-
nists, gemﬁbrozil, and rosiglitazone in streptozotocin diabetic apol-
ipoprotein E knockout mice [32, 33].
(ROS) that exceeds local antioxidant capacity. In particular,
diabetes is associated with the activation of enzymes that
directly liberate ROS, including NAD(P)H oxidase [52].
The potential importance of this pathway is illustrated
by ﬁndings demonstrating that pharmacological inhibition
of NAD(P)H oxidase with apocynin prevents mesangial
matrix expansion seen in experimental diabetic nephropathy
[53]. We have previously shown that NADPH-dependent
superoxide production was increased in the vasculature of
diabetic mice and that this may be attenuated following
treatment with the PPARα agonist, gemﬁbrozil (Figure 2)
[52]. In addition, gemﬁbrozil attenuated gene expression of
each of NAD(P)Hoxidase subunits including Cybb, Ncf1and
Rac1, the genes encoding gp91phox, p47phox, and Rac-1,
respectively. TGF-β-induced oxidative stress in mesangial
cells can also be attenuated by PPARα agonist, cloﬁbrate
[54]. These ﬁndings are consistent with those of Evans
et al., who demonstrated a reduction in oxidative stress after
3 months of treatmentwith ciproﬁbrate in subjectswith type
2 diabetes [55]. Another major source and target of ROS in
diabetes appears to be the mitochondria [56, 57], which gen-
erate the damaging superoxide anion O2
•− associated with
dysfunction of the mitochondrial respiratory chain. Selective
mitochondrial antioxidants, like mitoQ, have been shown to
have renoprotective actions in experimental diabetes [58].
Recent data suggest that mitochondrial function may also
be modiﬁed by PPARα agonists, potentially contributing to
their antioxidant and renoprotective actions [59].
3.3.2. PPARα Agonists as Anti-Inﬂammatory Agents. Inﬂam-
mation also plays a signiﬁcant role in the development and
progression of diabetic kidney disease, through the action
ofinﬂammatorycytokines,leucocyterecruitment,andendo-
theli-al dysfunction. Anti-inﬂammatory strategies have long
been known to be eﬀective in diabetic kidney disease. For
example, NSAIDs and COX-2 inhibitors both reduce albu-
minuria in patients with diabetic kidney disease, although4 PPAR Research
these actions are partly haemodynamic due to inhibition
of prostaglandin synthesis. PPARα agonists exert a range
of anti-inﬂammatory actions which may be beneﬁcial in
diabetic kidney disease. For example, treatment with ﬁbrates
is able to suppress circulating levels of cytokines in patients
with diabetes [60, 61]. Treatment with ﬁbrates has been
shown to reduce renal inﬂammation and tubulointerstitial
ﬁbrosis in diabetic fatty rats, an animal model of type 2
diabetes [62]. In particular, PPARα agonists appear to reduce
the expression of key adhesion molecules reducing VCAM
expression [63] thereby reducing monocyte recruitment and
subsequent activation [64, 65].
3.3.3. PPARα Agonists and Podocyte Biology. The glomerular
podocyte plays a key role in the development and pro-
gression of albuminuria and glomerulosclerosis associated
with diabetes [66–69]. Indeed, recent studies show that mice
with speciﬁc deletion of the insulin receptor only from their
podocytes develop signiﬁcant albuminuria together with
histological features that recapitulate diabetic nephropathy,
but in a normoglycemic environment [70]. Such data place
podocytes, and more particularly the dysregulation of their
growth and diﬀerentiation, at the very centre of the patho-
genesis of nephropathy. Podocytes clearly express PPARα
but more importantly podocyte injury may be attenuated
following treatment with PPAR agonists, both in vitro [71]
a n di nv i v o[ 27, 72–74]. For example, PPARα agonists
are also able to increase gene expression of the key slit-
pore protein, nephrin, in diabetic nephropathy, potentially
contributing to their antiproteinuric actions [27].
3.4. Other Renal Actions of PPARα Agonists. The renal action
ofPPARagonistsaremademorecomplicatedbytheiractions
on creatinine clearance and sodium retention, attributable to
PPARα and PPARγ activation, respectively. Treatment with
ﬁbrates is associated with a reversible increase in serum
creatinine of 10–15% which equates to a decline in estimated
GFR of between 10 and 15mL/min/1.73m2. In individuals
with diabetes, one quarter of whom had an eGFR less than
60mL/min, this represents a very signiﬁcant loss of function.
This is not renal damage and is fully reversible event after
3-4 years of therapy, as observed in the FIELD trial [75].
However, it is functional renal impairment nonetheless. It
has been argued that is one of the mechanisms by which
ﬁbrates might protect the kidney from overwork. However,
the precise mechanism of action remains to be established.
It has been suggested that PPARα agonists may inhibit
prostaglandinproduction,akeyregulatorofrenalbloodﬂow
and diabetic renal pathology, may also be responsible [76].
4. The Renoprotective Effects of
PPARγ Agonists
4.1. Experimental Studies. A number of studies have sug-
gestedthatPPARγ agonistshavedirectrenoprotectiveactions
in experimental diabetes [25–31]. For example, we have
shown that treatment with the PPARγ agonist, rosiglitazone
(20mg/kg/day), attenuated glomerulosclerosis, tubulointer-
stitial expansion, and collagen IV deposition following the
induction of streptozotocin diabetes (Figure 1)[ 25]. The
increase in albuminuria and the decline in kidney function
associated with diabetes in this model were attenuated in
the absence of changes in glucose, insulin, or lipid levels or
a reduction in blood pressure, suggesting a direct mecha-
nism of action (see below). Similar renoprotective actions
on diabetic kidney disease in other rodent models have
also been observed, including in db/db mice, obese Zucker
rats, and OLETF (Otsuka Long-Evans Tokushima Fatty) rats
[26–31]. In other models of advanced kidney disease, such
as in 5/6 nephrectomized rats, PPAR agonists are able to
attenuate proteinuria and glomerulosclerosis, independent
of glycemic control [77]. Even in the normal aging process,
the PPARγ agonist, pioglitazone can protect against normal-
age-associated renal injury by reducing proteinuria, sclerosis
and improving GFR [78].
4.2. Clinical Studies. A large number of clinical trials have
demonstrated that TZDs can also reduce albuminuria pa-
tients with type 2 diabetes. A recent meta-analysis including
15 of these randomised controlled studies (5 with rosiglita-
zone and 10 with pioglitazone) suggested that TZD treat-
ment, was associated with a signiﬁcant fall in urinary albu-
min excretion [79] .T h em a g n i t u d eo ft h i se ﬀect is again
similar to that achieved with PPARα agonists, approximately
10–20%, and appeared to be independent of improved gly-
caemic control. However, treatment with the PPARγ agonist,
pioglitazone was associated with greater decline in estimated
GFR than with placebo [80].
Further evidence for a role of PPAR in diabetic kidney
disease also comes from polymorphism studies in patients
with diabetes and nephropathy. For example, the Pro12Ala
polymorphismhasbeenlinkedtoahigherincidenceofneph-
ropathy in patients with type 2 diabetes [81, 82]. The same
polymorphism is associated with progressive renal decline
and higher rates of ESRD and all-cause mortality in patients
withtype1diabetes[83].However,thesamepolymorphisms
appear to inﬂuence metabolic control, meaning that a direct
link cannot be assumed.
4.3.PotentialMechanismsofAction. PPARγ activationresults
in increased sensitivity to the metabolic actions of insulin,
partly by reversing lipotoxicity-induced insulin resistance. In
addition, TZDs have been shown to “rejuvenate” pancreatic
β-cells, reducing β-cell apoptosis, and increasing β-cell pro-
liferation, thus maintaining β-cell mass and function [84].
Resistancetotheactionsofinsulinisstronglyassociatedwith
renal complications of diabetes. By reducing insulin resis-
tance in the kidney and improving glycaemic control, PPARγ
activation may indirectly improve renal function. In addi-
tion, there is some evidence that insulin resistance plays a
more direct role in the pathogenesis of diabetic renal disease.
In particular, pathway-selective insulin resistance appears to
be associated with activation of pathogenic pathways due toPPAR Research 5
hyperinsulinism [85]. Indeed, recent studies show that mice
with speciﬁc deletion of the insulin receptor only from their
podocytes develop signiﬁcant albuminuria together with
histological features that recapitulate diabetic nephropathy,
but in a normoglycemic environment [70]. In experimental
studiesperformedinaratmodeloftype2diabetes,proteinu-
ria and TGF-β expression in the kidney are partly attenuated
by pioglitazone, without aﬀecting glycemic control [86].
PPARγ agonists also appear to have direct eﬀects on a
number of critical pathways that are implicated in the devel-
opment and progression of diabetic kidney disease, over and
above action on metabolic control. None of these actions
occurs in isolation, but they appear synergistically inter-
twined, consistent with the key role of the PPARγ signalling
pathway as a metabolic and cellular regulator.
4.3.1. PPARγ and Hypertension-PPARγ. Agonists may also
directly impact on blood pressure [87–89], one of the key
drivers of renal injury in the diabetic kidney. Despite this,
experimental and clinical studies have demonstrated that
PPARγ activation by TZDs commonly reduces blood pres-
sure and prevents the development of hypertension [90, 91].
In addition, the Pro12Ala polymorphism and mutations in
the PPARγ gene are associated with hypertension in humans
[92, 93]. It has been postulated that this antihypertensive
eﬀect may be due to increase in endothelial nitric oxide
biosynthesis, inhibition of the renin-angiotensin system,
and/orreducedvascularinﬂammation[88,90].However,the
exact mechanism remains to be established.
4.3.2. PPARγ and Oxidative Stress. We have previously
shown that NADPH-dependent superoxide production is
increased in the vasculature of diabetic mice and that this
may be attenuated following treatment with the PPARγ ago-
nist, rosiglitazone [94, 95]. This is associated with reduced
markers of oxidative stress, such as lipid peroxidation pro-
ducts [96], and improved levels of antioxidants such as
glutathione reductase, glutathione, and protein carbonyl
groups. PPARγ agonist rosiglitazone or PPARγ overexpres-
sion is also able to protect against podocyte injury inducted
by aldosterone [71], potentially reﬂecting their role in
mitochondrial biogenesis and oxidative metabolism [97].
PPARγ activation is also able to attenuate AGE-induced ROS
generation and decrease RAGE expression [98].
4.3.3. PPARγ and Renal Hypertrophy. As noted above, dia-
betes is characterized by maladaptive renal hypertrophy.
We have previously shown that treatment of diabetic mice
with the PPARγ agonists, rosiglitazone, is able to reduce
renal hypertrophy associated with STZ diabetes [25]a n d
uninephrectomized db/db mice [99]. It has been suggested
that activation of PPARγ is able to directly modify cell
cycle signaling [100]. Certainly, pioglitazone ameliorates
downregulating the induction of p27 in glomerular cells and
reversing high glucose-induced cell hypertrophy in OLETF
rats[96].Othereﬀectsongrowthfactorsandindirectactions
via improved glycaemic control probably also contribute to
reduce renal hypertrophy observed with PPARγ agonists.
4.3.4. PPARγ and Inﬂammation. Inﬂammation also plays a
signiﬁcant role in the development and progression of dia-
betickidneydisease.TreatmentwithTZDsisabletosuppress
circulating levels of cytokines in patients with diabetes
[60, 61]. It has been suggested that TZDs ameliorate renal
injury in diabetic rats partly through inhibition of ICAM-1
expression,NF-κBactivation,andmacrophageinﬁltrationin
the kidney [101].
4.3.5.PPARγ andPodocyteBiology. Theglomerularpodocyte
plays a key role in the development and progression of albu-
minuria and glomerulosclerosis associated with diabetes
[66–69]. Such data place podocytes, and more particularly
the dysregulation of their growth and diﬀerentiation, at the
very centre of the pathogenesis of nephropathy. Podocytes
clearly express PPAR; but more importantly podocyte injury
may be attenuated following treatment with PPAR agonists,
both in vitro [71] and in vivo [27, 72–74]. For example,
PPARα agonists are also able to increase gene expression of
the key slit-pore protein, nephrin, in diabetic nephropathy,
potentially contributing to their antiproteinuric actions
[27]. PPARγ agonists also aﬀect nephrin gene transcription
[74]. Indeed, in cultured podocytes, TZDs are able to
directly reduce apoptosis and injury and improve podocyte
diﬀerentiation [71]. Similarly in an immune model of pro-
gressivenephropathy,passiveHeymannnephritis,thePPARγ
agonist, pioglitazone, had an antiproteinuric eﬀect, possibly
via transcriptional regulation of nephrin [74].
4.3.6. PPARγ and Renal Fibrogensis. It is thought that PPAR
activation inﬂuences many compenents of ﬁbrogenesis, in-
cluding the synthesis of matrix proteins, the expression of
ﬁbrogenic growth factors like TGF-β and CTGF, as well as
metalloprotease activity. Certainly, treatment with PPARγ
agonists is able to reduce glomeruloscleoriss and tubu-
lointerstitial ﬁbrosis in diabetic mice (Figure 1)[ 25]. In
mesangial cells exposed to high glucose PPARγ prevents the
upregulation of collagen IV [102].
4.3.7. PPARγ and Podocyte Biology and Adiponectin. Adi-
ponectin is widely considered to be a renoprotective adipok-
ine. Certainly, adiponectin-deﬁcient mice exhibit increased
albuminuria and podocyte foot process eﬀacement, which
can be rescued following exogenous administration of ad-
iponectin [103]. Adiponectin is a direct target gene of
PPARγ. Treatment of rosiglitazone or pioglitazone markedly
increases the adiponectin levels, alongside reductions in pro-
teinuria [104].
4.4. Other Renal Actions of PPARγ Agonists. Treatment with
PPARγ agonists is limited by several common adverse eﬀects,
including substantial weight gain and ﬂuid retention. This6 PPAR Research
is thought to be the result of upregulation of the epithelial
sodium channel in the kidney [105], promoting ﬂuid reten-
tion. In addition, activation of PPARγ results in activation of
the sympathetic nervous system, increased endothelial per-
meability [106], and increased renin expression.
5. TheRenoprotectiveEffectsofPPARδAgonists
5.1. Experimental Studies. Although PPARδ is ubiquitously
expressed in all nephron segments, its role in the kidney
remains to be fully established. The potential actions of
PPARδ agonists in the diabetic kidney have only been
recently explored. In streptozotocin-induced diabetes, the
expression of PPARδ is increased in the kidney [23], associ-
ated with the development and progression of renal damage.
By contrast, the selective PPARδ agonist GW0742 reduces
albuminuria, glomerular mesangial expansion, renal inﬂam-
mation, and collagen accumulation, without signiﬁcantly
aﬀecting blood glucose levels [107, 108].
5.2. Clinical Studies. Some studies have suggested that there
is an association between the metabolic phenotype and
polymorphismsofthePPARδ gene[109].Inhumans,PPARδ
agonists decrease plasma triglycerides and increase high-
densitylipoprotein(HDL)cholesterol[110].Intheory,treat-
ment of dysliipidaemia would be expected to also have
renoprotective beneﬁts [38–41]. However, as yet no studies
have been published to test this hypothesis.
5.3. Potential Mechanisms of Action. As noted above, dyslip-
idaemia is a major reversible risk factor for diabetic CKD
[38–41]. The reversal of dyslpidaemia following treatment
with PPARα may be partly responsible for the renoprotective
actions of these agents. Activation of the PPARδ receptor is
thought to alter the circulating lipid proﬁle by enhancement
of fat oxidation in skeletal muscle. PPARδ knockout mice
are also insulin resistant/glucose intolerant, although this
may reﬂect lipotoxicity rather than a direct eﬀect on insulin
sensitivity. PPARδ agonists may also have direct eﬀects on
a number of critical pathways that are implicated in the
developmentandprogressionofdiabetickidneydisease,over
and above action on metabolic control.
5.3.1. PPARδ and Hypoxia. Some data suggest that PPARδ is
involved in the regulation of apoptosis in response to renal
injury [111]. Deﬁciency of PPARδ increases susceptibility
to ischemic injury in the kidney, while selective agonists of
PPARδ protect against ischemic acute renal failure [111].
Certainly, hypoxia is known to be an important factor in
the pathogenesis of diabetic kidney disease [112], implying
that this eﬀect may be important in the diabetic kidney. In
addition,theexpressionofPPARδ isincreasedinthediabetic
kidney [107].
5.3.2. PPARδ and Inﬂammation. Activation of the PPARδ
receptor appears to have anti-inﬂammatory actions in the
kidney [113]. It is known that unliganded PPARδ binds
to the anti-inﬂammatory transcriptional repressor Bcl-6,
inhibiting its suppressive actions on inﬂammation [114].
Certainly, treatment with the PPARδ agonist GW0742
reduces macrophage inﬁltration in the diabetic kidney [107].
Whether this is a direct eﬀect on the kidney or on the
macrophages recruited by renal injury remains to be estab-
lished. Treatment of macrophages with GW0742 reverses
glucose-induced induction of pro-inﬂammatory mediators
like macrophage chemotaxis factor-1 (MCP-1). However,
more recent studies have suggested that PPARδ is not
essential for the anti-inﬂammatory eﬀect of some of the so-
calledselectivePPARδ receptorligands,suggestingthatother
pathways may also be involved [113].
5.3.3.PPARδ andAGE/RAGE. TheAGE/RAGEpathwayshas
been strongly implicated in the pathogenesis of diabetic kid-
ney disease. Activation of the PPARδ receptor in diabetic
mice is reduced following treatment with the PPARδ agonist,
L-165041 [108]. Certainly, L-165041 reduces AGE-mediated
apoptosis and inﬂammation in vitro [115], partly by this
pathway.
6. Conclusions
PPAR agonists have clear and reproducible renoprotective
eﬀects, impacting on a range of pathways implicated with
the development and progression of diabetic kidney disease,
including oxidative stress. For the TZDs, the cardiovascular
t o x i c i t y ,ﬂ u i dr e t e n t i o n ,a n dr i s ko fb l a d d e rc a n c e rh a v en o w
overshadowed these important renoprotective actions. How-
ever, the new recognition of ﬁbrates as agents that prevent
microvascular complications of diabetes will hopefully leads
to renewed interest in the role of PPARs in the kidney.
The actions of the glitazars, highly potent combined
PPAR α/γ agonists is also salutary. Although many times
more eﬀective activators of PPAR receptors, these agents
appeared no more eﬀective than currently available agonists,
while having a poorer side eﬀect proﬁle. It may be that PPAR
agonists also have activities through PPAR-independent
pathways, possibly via the transrepression of pathogenic
genes, such as activator protein-1 (AP-1) and nuclear factor-
κB(NF -κB)[6].S uc hacti vityma yo nl yloosel yc o rr elat ewith
activation of the PPAR receptor [7]. Greater understanding
of the exact mechanism of this pleiotropism will open the
way for new therapeutics for the prevention of diabetic
kidney disease.
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